Cargando…
Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test
It has been over two years since the COVID-19 pandemic began and it is still an unprecedented global challenge. Here, we aim to characterize the antibody profile from a large batch of early COVID-19 cases in China, from January – March 2020. More than 1,000 serum samples from participants in Hubei a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204641/ https://www.ncbi.nlm.nih.gov/pubmed/35719335 http://dx.doi.org/10.3389/fcimb.2022.915751 |
_version_ | 1784728971397562368 |
---|---|
author | Pu, Yiyi Weng, Youhong Wu, Yahan Gao, Fei Zheng, Xiaojun Xiong, Xianqin Lv, Hangjun Kong, Qingming |
author_facet | Pu, Yiyi Weng, Youhong Wu, Yahan Gao, Fei Zheng, Xiaojun Xiong, Xianqin Lv, Hangjun Kong, Qingming |
author_sort | Pu, Yiyi |
collection | PubMed |
description | It has been over two years since the COVID-19 pandemic began and it is still an unprecedented global challenge. Here, we aim to characterize the antibody profile from a large batch of early COVID-19 cases in China, from January – March 2020. More than 1,000 serum samples from participants in Hubei and Zhejiang province were collected. A series of serum samples were also collected along the disease course from 70 patients in Shanghai and Chongqing for longitudinal analysis. The serologic assay (ALLtest) we developed was confirmed to have high sensitivity (92.58% - 97.55%) and high specificity (92.14% - 96.28%) for the detection of SARS-CoV-2 nucleocapsid-specific antibodies. Confirmed cases found in the Hubei Provincial Center for Disease Control and Prevention (HBCDC), showed a significantly (p = 0.0018) higher positive rate from the ALLtest than RNA test. Then, we further identified the disease course, age, sex, and symptoms that were correlating factors with our ALLtest results. In summary, we confirmed the high reliability of our ALLtest and its important role in COVID-19 diagnosis. The correlating factors we identified will require special attention during future clinical application. |
format | Online Article Text |
id | pubmed-9204641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92046412022-06-18 Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test Pu, Yiyi Weng, Youhong Wu, Yahan Gao, Fei Zheng, Xiaojun Xiong, Xianqin Lv, Hangjun Kong, Qingming Front Cell Infect Microbiol Cellular and Infection Microbiology It has been over two years since the COVID-19 pandemic began and it is still an unprecedented global challenge. Here, we aim to characterize the antibody profile from a large batch of early COVID-19 cases in China, from January – March 2020. More than 1,000 serum samples from participants in Hubei and Zhejiang province were collected. A series of serum samples were also collected along the disease course from 70 patients in Shanghai and Chongqing for longitudinal analysis. The serologic assay (ALLtest) we developed was confirmed to have high sensitivity (92.58% - 97.55%) and high specificity (92.14% - 96.28%) for the detection of SARS-CoV-2 nucleocapsid-specific antibodies. Confirmed cases found in the Hubei Provincial Center for Disease Control and Prevention (HBCDC), showed a significantly (p = 0.0018) higher positive rate from the ALLtest than RNA test. Then, we further identified the disease course, age, sex, and symptoms that were correlating factors with our ALLtest results. In summary, we confirmed the high reliability of our ALLtest and its important role in COVID-19 diagnosis. The correlating factors we identified will require special attention during future clinical application. Frontiers Media S.A. 2022-05-27 /pmc/articles/PMC9204641/ /pubmed/35719335 http://dx.doi.org/10.3389/fcimb.2022.915751 Text en Copyright © 2022 Pu, Weng, Wu, Gao, Zheng, Xiong, Lv and Kong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Pu, Yiyi Weng, Youhong Wu, Yahan Gao, Fei Zheng, Xiaojun Xiong, Xianqin Lv, Hangjun Kong, Qingming Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test |
title | Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test |
title_full | Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test |
title_fullStr | Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test |
title_full_unstemmed | Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test |
title_short | Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test |
title_sort | antibody response to sars-cov-2 in the first batch of covid-19 patients in china by a self-developed rapid igm-igg test |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204641/ https://www.ncbi.nlm.nih.gov/pubmed/35719335 http://dx.doi.org/10.3389/fcimb.2022.915751 |
work_keys_str_mv | AT puyiyi antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest AT wengyouhong antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest AT wuyahan antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest AT gaofei antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest AT zhengxiaojun antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest AT xiongxianqin antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest AT lvhangjun antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest AT kongqingming antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest |